表紙
市場調查報告書

囊狀纖維化症市場分析、預測:∼2025年

Cystic Fibrosis Forecast and Market Analysis to 2025

出版商 Datamonitor Healthcare 商品編碼 858183
出版日期 內容資訊 英文 336 Pages
商品交期: 最快1-2個工作天內
價格
囊狀纖維化症市場分析、預測:∼2025年 Cystic Fibrosis Forecast and Market Analysis to 2025
出版日期: 2018年09月03日內容資訊: 英文 336 Pages
簡介

囊狀纖維化症患者的預後由於新的治療方法的出現,這數十年顯著改善,患者的平均壽命延長37年。

本報告提供囊狀纖維化症的市場調查,疾病的臨床性概要,目前治療選擇,處方趨勢,未滿足需求,已上市產品的簡介,開發平台後期的產品的簡介等資料彙整。

預測:囊狀纖維化症

  • 概要
  • 市場動態
  • 預測、未來趨勢
  • 市場定義、調查手法
  • 文獻
  • 產品簡介:BRONCHITOL
  • 產品簡介:CAYSTON
  • 產品簡介:COLOBREATHE
  • 產品簡介:KALYDECO
  • 產品簡介:ORKAMBI
  • 產品簡介:PULMOZYME
  • 產品簡介:QUINSAIR
  • 產品簡介:SYMDEKO
  • 產品簡介:TOBI/TOBI PODHALER
  • 產品簡介 (開發後期):VERTEX TRIPLE COMBINATION PROGRAM

治療:囊狀纖維化症

  • 概要
  • 摘要整理
  • 疾病定義、診斷
  • 患者區分
  • 目前治療選擇
  • 處方趨勢
  • 未滿足需求

流行病學:囊狀纖維化症

  • 概要
  • 疾病的背景
  • 調查手法
  • 預測
  • 文獻
  • 附錄

已上市藥物:囊狀纖維化症

  • 概要
  • 產品概要
  • 產品簡介:BRONCHITOL
  • 產品簡介:CAYSTON
  • 產品簡介:COLOBREATHE
  • 產品簡介:KALYDECO
  • 產品簡介:ORKAMBI
  • 產品簡介:PULMOZYME
  • 產品簡介:QUINSAIR
  • 產品簡介:SYMDEKO
  • 產品簡介:TOBI/TOBI PODHALER

開發平台:囊狀纖維化症

  • 概要
  • 臨床實驗平台:概要
  • 其他的資訊來源
  • 產品簡介 (開發後期):ARIKAYCE
  • 產品簡介 (開發後期):VERTEX TRIPLE COMBINATION PROGRAM
目錄
Product Code: DMKC5972

Overview

Cystic fibrosis, caused by mutations in cystic fibrosis transmembrane conductance regulator (CFTR) protein, is a rare and life-limiting genetic disorder that is characterized by thick, sticky mucus and pulmonary complications. The prognosis of patients has improved markedly over recent decades with the advent of new treatments, increasing the mean life expectancy of patients to 37 years. These include inhaled antibiotics for managing chronic lung infections, as well as mucolytics that facilitate the breakdown and clearance of mucus from the lungs, improving airflow and decreasing the risk of infection.

Recent events and opinion:

  • Vertex is building a durable $7bn portfolio of CFTR modulators.
  • Uptake of latest wave of therapies will uphold improvements in prognosis and life expectancy seen in recent decades.
  • Prevalent cases are expected to increase over the forecast period mainly due to improving survival rates.
  • Vertex's dominance of the cystic fibrosis market is set to continue.
  • Triple combination therapies with Kalydeco-like efficacy and broad label coverage set foundation for blockbuster status.

TABLE OF CONTENTS

FORECAST: CYSTIC FIBROSIS (Published on 03 September 2018)

  • OVERVIEW
  • MARKET DYNAMICS
  • FORECAST AND FUTURE TRENDS
  • MARKET DEFINITION AND METHODOLOGY
  • PRIMARY RESEARCH METHODOLOGY
  • BIBLIOGRAPHY
  • PRODUCT PROFILE: BRONCHITOL
  • PRODUCT PROFILE: CAYSTON
  • PRODUCT PROFILE: COLOBREATHE
  • PRODUCT PROFILE: KALYDECO
  • PRODUCT PROFILE: ORKAMBI
  • PRODUCT PROFILE: PULMOZYME
  • PRODUCT PROFILE: QUINSAIR
  • PRODUCT PROFILE: SYMDEKO
  • PRODUCT PROFILE: TOBI/TOBI PODHALER
  • PRODUCT PROFILE (LATE STAGE): VERTEX TRIPLE COMBINATION PROGRAM

TREATMENT: CYSTIC FIBROSIS (Published on 03 September 2018)

  • OVERVIEW
  • EXECUTIVE SUMMARY
  • PRIMARY RESEARCH METHODOLOGY
  • DISEASE DEFINITION AND DIAGNOSIS
  • PATIENT SEGMENTATION
  • CURRENT TREATMENT OPTIONS
  • PRESCRIBING TRENDS
  • UNMET NEEDS IN CYSTIC FIBROSIS

EPIDEMIOLOGY: CYSTIC FIBROSIS (Published on 06 September 2018)

  • OVERVIEW
  • DISEASE BACKGROUND
  • METHODOLOGY
  • FORECAST
  • BIBLIOGRAPHY
  • APPENDIX

MARKETED DRUGS: CYSTIC FIBROSIS (Published on 03 September 2018)

  • OVERVIEW
  • PRODUCT OVERVIEW
  • PRODUCT PROFILE: BRONCHITOL
  • PRODUCT PROFILE: CAYSTON
  • PRODUCT PROFILE: COLOBREATHE
  • PRODUCT PROFILE: KALYDECO
  • PRODUCT PROFILE: ORKAMBI
  • PRODUCT PROFILE: PULMOZYME
  • PRODUCT PROFILE: QUINSAIR
  • PRODUCT PROFILE: SYMDEKO
  • PRODUCT PROFILE: TOBI/TOBI PODHALER

PIPELINE: CYSTIC FIBROSIS (Published on 03 September 2018)

  • OVERVIEW
  • CLINICAL PIPELINE OVERVIEW
  • ADDITIONAL PHARMA INTELLIGENCE PIPELINE RESOURCES
  • PRODUCT PROFILE (LATE STAGE): ARIKAYCE
  • PRODUCT PROFILE (LATE STAGE): VERTEX TRIPLE COMBINATION PROGRAM

LIST OF FIGURES

  • Figure 1: Cystic fibrosis - current and future market dynamics analysis
  • Figure 2: Datamonitor Healthcare's assessment summary of key marketed and pipeline drugs for cystic fibrosis
  • Figure 3: Cystic fibrosis drug sales across the US and five major EU markets, by country, 2016-25
  • Figure 4: Growth dynamics of the cystic fibrosis market in the US and five major EU markets, by country, 2016-25
  • Figure 5: Cystic fibrosis drug sales across the US and five major EU markets, by drug class, 2016-25
  • Figure 6: Methodology flow for Datamonitor Healthcare's cystic fibrosis forecast
  • Figure 7: Price sources and calculations, by country
  • Figure 8: Bronchitol for cystic fibrosis - SWOT analysis
  • Figure 9: Datamonitor Healthcare's drug assessment summary of Bronchitol for cystic fibrosis
  • Figure 10: Datamonitor Healthcare's drug assessment summary of Bronchitol for cystic fibrosis
  • Figure 11: Bronchitol sales for cystic fibrosis across the US, Germany, and the UK, by country, 2016-25
  • Figure 12: Cayston for cystic fibrosis - SWOT analysis
  • Figure 13: Datamonitor Healthcare's drug assessment summary of Cayston for cystic fibrosis
  • Figure 14: Datamonitor Healthcare's drug assessment summary of Cayston for cystic fibrosis
  • Figure 15: Cayston sales for cystic fibrosis across the US and five major EU markets, by country, 2016-25
  • Figure 16: Colobreathe for cystic fibrosis - SWOT analysis
  • Figure 17: Datamonitor Healthcare's drug assessment summary of Colobreathe for cystic fibrosis
  • Figure 18: Datamonitor Healthcare's drug assessment summary of Colobreathe for cystic fibrosis
  • Figure 19: Colobreathe sales for cystic fibrosis across the five major EU markets, by country, 2016-25
  • Figure 20: Kalydeco for cystic fibrosis - SWOT analysis
  • Figure 21: Datamonitor Healthcare's drug assessment summary of Kalydeco for cystic fibrosis
  • Figure 22: Datamonitor Healthcare's drug assessment summary of Kalydeco for cystic fibrosis
  • Figure 23: Kalydeco sales for cystic fibrosis across the US and five major EU markets, by country, 2016-25
  • Figure 24: Orkambi for cystic fibrosis - SWOT analysis
  • Figure 25: Datamonitor Healthcare's drug assessment summary of Orkambi for cystic fibrosis
  • Figure 26: Datamonitor Healthcare's drug assessment summary of Orkambi for cystic fibrosis
  • Figure 27: Orkambi sales for cystic fibrosis across the US and five major EU markets, by country, 2016-25
  • Figure 28: Pulmozyme for cystic fibrosis - SWOT analysis
  • Figure 29: Datamonitor Healthcare's drug assessment summary of Pulmozyme for cystic fibrosis
  • Figure 30: Datamonitor Healthcare's drug assessment summary of Pulmozyme for cystic fibrosis
  • Figure 31: Pulmozyme sales for cystic fibrosis across the US and five major EU markets, by country, 2016-25
  • Figure 32: Quinsair for cystic fibrosis - SWOT analysis
  • Figure 33: Datamonitor Healthcare's drug assessment summary of Quinsair for cystic fibrosis
  • Figure 34: Datamonitor Healthcare's drug assessment summary of Quinsair for cystic fibrosis
  • Figure 35: Quinsair sales for cystic fibrosis across the five major EU markets, by country, 2016-25
  • Figure 36: Symdeko for cystic fibrosis - SWOT analysis
  • Figure 37: Datamonitor Healthcare's drug assessment summary of Symdeko for cystic fibrosis
  • Figure 38: Datamonitor Healthcare's drug assessment summary of Symdeko for cystic fibrosis
  • Figure 39: Symdeko sales for cystic fibrosis across the US and five major EU markets, by country, 2016-25
  • Figure 40: Tobi/Tobi Podhaler for cystic fibrosis - SWOT analysis
  • Figure 41: Datamonitor Healthcare's drug assessment summary of Tobi/Tobi Podhaler for cystic fibrosis
  • Figure 42: Datamonitor Healthcare's drug assessment summary of Tobi/Tobi Podhaler for cystic fibrosis
  • Figure 43: Tobi/Tobi Podhaler sales for cystic fibrosis across the US and five major EU markets, by country, 2016-25
  • Figure 44: Vertex triple combination program for cystic fibrosis - SWOT analysis
  • Figure 45: Datamonitor Healthcare's drug assessment summary of Vertex triple combination program for cystic fibrosis
  • Figure 46: Datamonitor Healthcare's drug assessment summary of Vertex triple combination program for cystic fibrosis
  • Figure 47: Vertex triple combination program sales for cystic fibrosis across the US and five major EU markets, by country, 2016-25
  • Figure 48: Proportion of cystic fibrosis patients with an unknown mutation status, 2016
  • Figure 49: Prevalence of F508del mutations among surveyed pulmonologists, by country
  • Figure 50: Use of airway clearance techniques among surveyed pulmonologists' cystic fibrosis patients, by country, 2016
  • Figure 51: Treatments for pancreatic symptoms among surveyed pulmonologists' cystic fibrosis patients, by country, 2016
  • Figure 52: Treatment strategies for pulmonary symptoms among surveyed pulmonologists' cystic fibrosis patients, by country, 2016
  • Figure 53: Top five therapies among cystic fibrosis patients receiving chronic antibiotics, 2016
  • Figure 54: Top therapies among cystic fibrosis patients receiving mucolytics, 2016
  • Figure 55: Top therapies among cystic fibrosis patients receiving CFTR modulators, 2016
  • Figure 56: Top five therapies among cystic fibrosis patients receiving bronchodilators, 2016
  • Figure 57: Compliance rates of cystic fibrosis patients, by therapy type and country, 2016
  • Figure 58: Treatment rates for non-pulmonary symptoms among surveyed pulmonologists' cystic fibrosis patients, by country, 2016
  • Figure 59: Key unmet needs for cystic fibrosis, 2016
  • Figure 60: Trends in diagnosed prevalent cases of cystic fibrosis in the US and five major EU markets, by country, 2017-37
  • Figure 61: Bronchitol for cystic fibrosis - SWOT analysis
  • Figure 62: Datamonitor Healthcare's drug assessment summary of Bronchitol for cystic fibrosis
  • Figure 63: Datamonitor Healthcare's drug assessment summary of Bronchitol for cystic fibrosis
  • Figure 64: Bronchitol sales for cystic fibrosis across the US, Germany, and the UK, by country, 2016-25
  • Figure 65: Cayston for cystic fibrosis - SWOT analysis
  • Figure 66: Datamonitor Healthcare's drug assessment summary of Cayston for cystic fibrosis
  • Figure 67: Datamonitor Healthcare's drug assessment summary of Cayston for cystic fibrosis
  • Figure 68: Cayston sales for cystic fibrosis across the US and five major EU markets, by country, 2016-25
  • Figure 69: Colobreathe for cystic fibrosis - SWOT analysis
  • Figure 70: Datamonitor Healthcare's drug assessment summary of Colobreathe for cystic fibrosis
  • Figure 71: Datamonitor Healthcare's drug assessment summary of Colobreathe for cystic fibrosis
  • Figure 72: Colobreathe sales for cystic fibrosis across the five major EU markets, by country, 2016-25
  • Figure 73: Kalydeco for cystic fibrosis - SWOT analysis
  • Figure 74: Datamonitor Healthcare's drug assessment summary of Kalydeco for cystic fibrosis
  • Figure 75: Datamonitor Healthcare's drug assessment summary of Kalydeco for cystic fibrosis
  • Figure 76: Kalydeco sales for cystic fibrosis across the US and five major EU markets, by country, 2016-25
  • Figure 77: Orkambi for cystic fibrosis - SWOT analysis
  • Figure 78: Datamonitor Healthcare's drug assessment summary of Orkambi for cystic fibrosis
  • Figure 79: Datamonitor Healthcare's drug assessment summary of Orkambi for cystic fibrosis
  • Figure 80: Orkambi sales for cystic fibrosis across the US and five major EU markets, by country, 2016-25
  • Figure 81: Pulmozyme for cystic fibrosis - SWOT analysis
  • Figure 82: Datamonitor Healthcare's drug assessment summary of Pulmozyme for cystic fibrosis
  • Figure 83: Datamonitor Healthcare's drug assessment summary of Pulmozyme for cystic fibrosis
  • Figure 84: Pulmozyme sales for cystic fibrosis across the US and five major EU markets, by country, 2016-25
  • Figure 85: Quinsair for cystic fibrosis - SWOT analysis
  • Figure 86: Datamonitor Healthcare's drug assessment summary of Quinsair for cystic fibrosis
  • Figure 87: Datamonitor Healthcare's drug assessment summary of Quinsair for cystic fibrosis
  • Figure 88: Quinsair sales for cystic fibrosis across the five major EU markets, by country, 2016-25
  • Figure 89: Symdeko for cystic fibrosis - SWOT analysis
  • Figure 90: Datamonitor Healthcare's drug assessment summary of Symdeko for cystic fibrosis
  • Figure 91: Datamonitor Healthcare's drug assessment summary of Symdeko for cystic fibrosis
  • Figure 92: Symdeko sales for cystic fibrosis across the US and five major EU markets, by country, 2016-25
  • Figure 93: Tobi/Tobi Podhaler for cystic fibrosis - SWOT analysis
  • Figure 94: Datamonitor Healthcare's drug assessment summary of Tobi/Tobi Podhaler for cystic fibrosis
  • Figure 95: Datamonitor Healthcare's drug assessment summary of Tobi/Tobi Podhaler for cystic fibrosis
  • Figure 96: Tobi/Tobi Podhaler sales for cystic fibrosis across the US and five major EU markets, by country, 2016-25
  • Figure 97: Arikayce for cystic fibrosis - SWOT analysis
  • Figure 98: Datamonitor Healthcare's drug assessment summary of Arikayce for cystic fibrosis
  • Figure 99: Datamonitor Healthcare's drug assessment summary of Arikayce for cystic fibrosis
  • Figure 100: Vertex triple combination program for cystic fibrosis - SWOT analysis
  • Figure 101: Datamonitor Healthcare's drug assessment summary of Vertex triple combination program for cystic fibrosis
  • Figure 102: Datamonitor Healthcare's drug assessment summary of Vertex triple combination program for cystic fibrosis
  • Figure 103: Vertex triple combination program sales for cystic fibrosis across the US and five major EU markets, by country, 2016-25

LIST OF TABLES

  • Table 1: Cystic fibrosis drug sales across the US and five major EU markets, by country ($m), 2016-25
  • Table 2: Cystic fibrosis drug sales across the US and five major EU markets, by drug class ($m), 2016-25
  • Table 3: Exchange rates used for calculating prices
  • Table 4: Pulmonologists and pediatric pulmonologists surveyed for the cystic fibrosis primary research study, 2016
  • Table 5: Therapies included within cystic fibrosis key opinion leader discussions
  • Table 6: Bronchitol drug profile
  • Table 7: Bronchitol Phase III data in cystic fibrosis
  • Table 8: Bronchitol sales for cystic fibrosis across the US, Germany, and the UK, by country ($m), 2016-25
  • Table 9: Bronchitol sales for cystic fibrosis across the US, Germany, and the UK, by country ($m), 2016-25
  • Table 10: Cayston drug profile
  • Table 11: Cayston Phase III data in cystic fibrosis
  • Table 12: Cayston sales for cystic fibrosis across the US and five major EU markets, by country ($m), 2016-25
  • Table 13: Colobreathe drug profile
  • Table 14: Colobreathe Phase III data in cystic fibrosis
  • Table 15: Colobreathe sales for cystic fibrosis across the five major EU markets, by country ($m), 2016-25
  • Table 16: Kalydeco drug profile
  • Table 17: Kalydeco Phase III data in cystic fibrosis
  • Table 18: Kalydeco sales for cystic fibrosis across the US and five major EU markets, by country ($m), 2016-25
  • Table 19: Orkambi drug profile
  • Table 20: Orkambi Phase III data in cystic fibrosis
  • Table 21: Orkambi sales for cystic fibrosis across the US and five major EU markets, by country ($m), 2016-25
  • Table 22: Pulmozyme drug profile
  • Table 23: Pulmozyme pivotal trial data in cystic fibrosis
  • Table 24: Pulmozyme sales for cystic fibrosis across the US and five major EU markets, by country ($m), 2016-25
  • Table 25: Quinsair drug profile
  • Table 26: Quinsair Phase Iib/III data in cystic fibrosis
  • Table 27: Quinsair sales for cystic fibrosis across the five major EU markets, by country ($m), 2016-25
  • Table 28: Symdeko drug profile
  • Table 29: Symdeko Phase III data in cystic fibrosis
  • Table 30: Symdeko sales for cystic fibrosis across the US and five major EU markets, by country ($m), 2016-25
  • Table 31: Tobi/Tobi Podhaler drug profile
  • Table 32: Tobi/Tobi Podhaler Phase III data in cystic fibrosis
  • Table 33: Tobi/Tobi Podhaler sales for cystic fibrosis across the US and five major EU markets, by country ($m), 2016-25
  • Table 34: Vertex triple combination program drug profile
  • Table 35: Vertex triple combination program Phase II data in cystic fibrosis
  • Table 36: Vertex triple combination program Phase III data in cystic fibrosis
  • Table 37: Vertex triple combination program sales for cystic fibrosis across the US and five major EU markets, by country ($m), 2016-25
  • Table 38: Pulmonologists and pediatric pulmonologists surveyed for the cystic fibrosis primary research study, 2016
  • Table 39: CFTR mutational classes and their impact on CFTR structure and function
  • Table 40: Phenotypic features consistent with a diagnosis of cystic fibrosis
  • Table 41: Approved treatments available for cystic fibrosis across the US and five major EU markets
  • Table 42: Cystic Fibrosis Foundation major treatment recommendations
  • Table 43: Patient shares of approved antibiotics for cystic fibrosis among patients receiving chronic antibiotic treatment, by country (%), 2016
  • Table 44: Patient shares of therapies among patients receiving treatment for pancreatic symptoms (%), 2016
  • Table 45: Sources used for epidemiological analysis of cystic fibrosis in the US and five major EU markets, by country
  • Table 46: Diagnosed prevalent cases of cystic fibrosis in the US and five major EU markets, by country, 2017-37
  • Table 47: Profiled key marketed drugs for cystic fibrosis
  • Table 48: Bronchitol drug profile
  • Table 49: Bronchitol Phase III data in cystic fibrosis
  • Table 50: Bronchitol sales for cystic fibrosis across the US, Germany, and the UK, by country ($m), 2016-25
  • Table 51: Bronchitol sales for cystic fibrosis across the US, Germany, and the UK, by country ($m), 2016-25
  • Table 52: Cayston drug profile
  • Table 53: Cayston Phase III data in cystic fibrosis
  • Table 54: Cayston sales for cystic fibrosis across the US and five major EU markets, by country ($m), 2016-25
  • Table 55: Colobreathe drug profile
  • Table 56: Colobreathe Phase III data in cystic fibrosis
  • Table 57: Colobreathe sales for cystic fibrosis across the five major EU markets, by country ($m), 2016-25
  • Table 58: Kalydeco drug profile
  • Table 59: Kalydeco Phase III data in cystic fibrosis
  • Table 60: Kalydeco sales for cystic fibrosis across the US and five major EU markets, by country ($m), 2016-25
  • Table 61: Orkambi drug profile
  • Table 62: Orkambi Phase III data in cystic fibrosis
  • Table 63: Orkambi sales for cystic fibrosis across the US and five major EU markets, by country ($m), 2016-25
  • Table 64: Pulmozyme drug profile
  • Table 65: Pulmozyme pivotal trial data in cystic fibrosis
  • Table 66: Pulmozyme sales for cystic fibrosis across the US and five major EU markets, by country ($m), 2016-25
  • Table 67: Quinsair drug profile
  • Table 68: Quinsair Phase Iib/III data in cystic fibrosis
  • Table 69: Quinsair sales for cystic fibrosis across the five major EU markets, by country ($m), 2016-25
  • Table 70: Symdeko drug profile
  • Table 71: Symdeko Phase III data in cystic fibrosis
  • Table 72: Symdeko sales for cystic fibrosis across the US and five major EU markets, by country ($m), 2016-25
  • Table 73: Tobi/Tobi Podhaler drug profile
  • Table 74: Tobi/Tobi Podhaler Phase III data in cystic fibrosis
  • Table 75: Tobi/Tobi Podhaler sales for cystic fibrosis across the US and five major EU markets, by country ($m), 2016-25
  • Table 76: Profiled pipeline products in development for cystic fibrosis
  • Table 77: Arikayce drug profile
  • Table 78: Arikayce Phase III data in cystic fibrosis
  • Table 79: Vertex triple combination program drug profile
  • Table 80: Vertex triple combination program Phase II data in cystic fibrosis
  • Table 81: Vertex triple combination program Phase III data in cystic fibrosis
  • Table 82: Vertex triple combination program sales for cystic fibrosis across the US and five major EU markets, by country ($m), 2016-25